Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Genmab Announces Data to be presented at SITC 35th Anniversary Annual Meeting

10/15/2020 | 08:23am EST

Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts for Genmab programs were accepted for presentation at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting.

Accepted abstracts include preliminary data from the first-in-human Phase 1/2a study of DuoBody-PD-L1x4-1BB (GEN1046), a bispecific antibody in joint development with BioNTech, in patients with advanced solid tumors, which was accepted for e-poster presentation. All abstracts are scheduled to be available on the SITC website on November 9, 2020.

'We are pleased that the first clinical data for DuoBody-PD-L1x4-1BB (GEN1046), which we are developing in collaboration with BioNTech, was selected for presentation at the SITC 35th Anniversary Annual Meeting,' said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. 'The preliminary Phase 1/2a data demonstrate the potential of DuoBody-PD-L1x4-1BB (GEN1046) in solid tumors and we look forward to this first data being shared with the medical community.'

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of the following approved antibodies: DARZALEX (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Kesimpta (subcutaneous ofatumumab, under agreement with Novartis AG), for the treatment of adults with relapsing forms of multiple sclerosis in the U.S. and TEPEZZA (teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. A subcutaneous formulation of daratumumab, known as DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in the U.S., has been approved in the U.S. and Europe for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy, Arzerra (ofatumumab, under agreement with Novartis AG), approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies the DuoBody platform for generation of bispecific antibodies, the HexaBody platform, which creates effector function enhanced antibodies, the HexElect platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.


Marisol Peron

Tel: +1 609 524 0065

Email: mmp@genmab.com

This Media Release contains forward looking statements. The words 'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -1.99% 118.68 Delayed Quote.250.30%
GENMAB A/S 0.17% 2363 Delayed Quote.59.23%
NOVARTIS AG -1.22% 80.92 Delayed Quote.-10.86%
All news about NOVARTIS AG
12/01NOVARTIS : Genentech Get Expanded FDA OK of Xolair for Nasal Polyps
11/29Swiss firms narrowly avoid 'Responsible Business' liability as vote divides n..
11/27NOVARTIS AG : Barclays reaffirms its Sell rating
11/26Business rights or human rights? Swiss vote shines spotlight on companies
11/25NOVARTIS : Genmab Announces Enapotamab Vedotin Update
11/25NOVARTIS AG : Bryan Garnier maintains a Buy rating
11/25NOVARTIS AG : UBS reiterates its Buy rating
11/25NOVARTIS AG : Goldman Sachs remains its Buy rating
11/24GLOBAL MARKETS LIVE: Tesla, Best Buy, Qantas…
11/24NOVARTIS AG : Goldman Sachs reaffirms its Buy rating
More news
Financials (USD)
Sales 2020 49 423 M - -
Net income 2020 8 322 M - -
Net Debt 2020 19 271 M - -
P/E ratio 2020 24,8x
Yield 2020 3,48%
Capitalization 207 B 207 B -
EV / Sales 2020 4,57x
EV / Sales 2021 4,21x
Nbr of Employees 110 000
Free-Float 86,9%
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 105,85 $
Last Close Price 90,82 $
Spread / Highest target 55,0%
Spread / Average Target 16,5%
Spread / Lowest Target -28,7%
EPS Revisions
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-10.86%206 585
JOHNSON & JOHNSON2.15%389 985
ROCHE HOLDING AG-3.61%289 019
PFIZER, INC.8.00%226 783
MERCK & CO., INC.-10.03%207 033
ABBVIE INC.18.58%185 357